The Different Roles of MET in the Development and Treatment of Cancer-Reference-Cited by-同舟云学术

The Different Roles of MET in the Development and Treatment of Cancer

Published:2023-10-21 Issue:20 Volume:15 Page:5087
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Mollerup Jens¹^ORCID,Jørgensen Jan Trøst²^ORCID

Affiliation:

1. Pathology Division, Agilent Technologies Denmark ApS, Produktionsvej 42, 2600 Glostrup, Denmark

2. Department: Medical Sciences, Dx-Rx Institute, Baunevaenget 76, 3480 Fredensborg, Denmark

Abstract

This Special Issue features contributions from leading international researchers in the field of MET (hepatocyte growth factor (HGF) receptor) biology and therapeutics [...]

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Link

https://www.mdpi.com/2072-6694/15/20/5087/pdf

Reference13 articles.

1. Heydt, C., Ihle, M.A., and Merkelbach-Bruse, S. (2023). Overview of Molecular Detection Technologies for MET in Lung Cancer. Cancers, 15.

2. Jie, G.-L., Peng, L.-X., Zheng, M.-M., Sun, H., Wang, S.-R., Liu, S.-Y.M., Yin, K., Chen, Z.-H., Tian, H.-X., and Yang, J.-J. (2023). Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC. Cancers, 15.

3. Das, R., Jakubowski, M.A., Spildener, J., and Cheng, Y.-W. (2022). Identification of Novel MET Exon 14 Skipping Variants in Non-Small Cell Lung Cancer Patients: A Prototype Workflow Involving in Silico Prediction and RT-PCR. Cancers, 14.

4. Kumaki, Y., Oda, G., and Ikeda, S. (2023). Targeting MET Amplification: Opportunities and Obstacles in Therapeutic Approaches. Cancers, 15.

5. Jørgensen, J.T., and Mollerup, J. (2022). Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC. Cancers, 14.